These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

556 related articles for article (PubMed ID: 18559585)

  • 1. The ethics of phase 0 oncology trials.
    Abdoler E; Taylor H; Wendler D
    Clin Cancer Res; 2008 Jun; 14(12):3692-7. PubMed ID: 18559585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
    Takimoto CH
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
    Kinders R; Parchment RE; Ji J; Kummar S; Murgo AJ; Gutierrez M; Collins J; Rubinstein L; Pickeral O; Steinberg SM; Yang S; Hollingshead M; Chen A; Helman L; Wiltrout R; Simpson M; Tomaszewski JE; Doroshow JH
    Mol Interv; 2007 Dec; 7(6):325-34. PubMed ID: 18199854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disclosure of conflicts of interest by authors of clinical trials and editorials in oncology.
    Riechelmann RP; Wang L; O'Carroll A; Krzyzanowska MK
    J Clin Oncol; 2007 Oct; 25(29):4642-7. PubMed ID: 17925561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does it matter whether investigators intend to benefit research subjects?
    Wendler D; Abdoler E
    Kennedy Inst Ethics J; 2010 Dec; 20(4):353-70. PubMed ID: 21338029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue collection for correlative studies in childhood cancer clinical trials: ethical considerations and special imperatives.
    Anderson BD; Adamson PC; Weiner SL; McCabe MS; Smith MA
    J Clin Oncol; 2004 Dec; 22(23):4846-50. PubMed ID: 15570088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefit in phase 1 oncology trials: therapeutic misconception or reasonable treatment option?
    Miller FG; Joffe S
    Clin Trials; 2008; 5(6):617-23. PubMed ID: 19029210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I research and the meaning of direct benefit.
    Ross L
    J Pediatr; 2006 Jul; 149(1 Suppl):S20-4. PubMed ID: 16829237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Informing prospective research subjects of the influence of regulatory requirements for drug approval on the design of clinical trials in oncology.
    Markman M
    Cancer; 2007 Mar; 109(6):1003-6. PubMed ID: 17311306
    [No Abstract]   [Full Text] [Related]  

  • 11. Descriptions of benefits and risks in consent forms for phase 1 oncology trials.
    Horng S; Emanuel EJ; Wilfond B; Rackoff J; Martz K; Grady C
    N Engl J Med; 2002 Dec; 347(26):2134-40. PubMed ID: 12501226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 0 clinical trials will overcome stagnation of anticancer drug development?
    Mendoza L
    Klin Onkol; 2011; 24(2):143-5. PubMed ID: 21638998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding informed consent for participation in international health research.
    Jegede AS
    Dev World Bioeth; 2009 Aug; 9(2):81-7. PubMed ID: 18637943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Towards the development of ethical practices in paediatric clinical trials: the special position of the terminally ill child.
    Keough WJ
    J Law Med; 2006 Feb; 13(3):370-86. PubMed ID: 16506728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Porsche for patient accrual.
    Steinberg D
    Cancer Invest; 2005; 23(8):741-3. PubMed ID: 16377593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ethics in oncology: consulting for the investment industry.
    Berlin J; Bruinooge SS; Tannock IF
    J Clin Oncol; 2007 Feb; 25(4):444-6. PubMed ID: 17264341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attitudes toward research participation and investigator conflicts of interest among advanced cancer patients participating in early phase clinical trials.
    Gray SW; Hlubocky FJ; Ratain MJ; Daugherty CK
    J Clin Oncol; 2007 Aug; 25(23):3488-94. PubMed ID: 17687154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reflections on ethical concerns arising from the incorporation of results of randomized trials of antineoplastic therapy into routine clinical practice.
    Markman M
    Cancer Invest; 2005; 23(8):735-40. PubMed ID: 16377592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ethical responsibility of phase 0 trials.
    Arai RJ; Hoff PM; de Castro G; Stern A
    Clin Cancer Res; 2009 Feb; 15(3):1121; author reply 1121-2. PubMed ID: 19188189
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 28.